LISA BOMGAARS to Venous Thromboembolism
This is a "connection" page, showing publications LISA BOMGAARS has written about Venous Thromboembolism.
Connection Strength
0.873
-
Dabigatran for Treatment and Secondary Prevention of Venous Thromboembolism in Pediatric Congenital Heart Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e028957.
Score: 0.177
-
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia. Blood Adv. 2022 11 22; 6(22):5908-5923.
Score: 0.162
-
Pharmacokinetic modeling and simulation support for age- and weight-adjusted dosing of dabigatran etexilate in children with venous thromboembolism. J Thromb Haemost. 2021 05; 19(5):1259-1270.
Score: 0.145
-
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan; 8(1):e22-e33.
Score: 0.142
-
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020 02 13; 135(7):491-504.
Score: 0.134
-
Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost. 2017 11; 15(11):2147-2157.
Score: 0.114